ARYA Sciences Acquisition Corp IV: Nasdaq/NYSE listing notice — ARYA Sciences SPAC gets Nasdaq delisting notice for failing to complete business combination within 36 months

ARYA Sciences Acquisition Corp IV

Received Nasdaq staff notice on Feb 26, 2024 for non-compliance with IM-5101-2 (36-month deadline).
Trading would be suspended March 6, 2024 unless hearing timely requested by March 4, 2024.
ARYA has requested a hearing before Nasdaq Hearings Panel to stay suspension and complete business combination with Adagio Medical, Inc.
No assurance ARYA will regain compliance or maintain Nasdaq listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ARYA Sciences Acquisition Corp IV received a nasdaq deficiency notice notice regarding other (rules IM-5101-2).

Exchange: nasdaq
Notice: deficiency notice
Rules: IM-5101-2

Exact text from the filing

February 26, 2024, ARYA Sciences Acquisition Corp IV (“ARYA”) received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, unless ARYA timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) by March 4, 2024, trading of ARYA’s securities on the Nasdaq Capital Market would be suspended at the opening of business on March 6, 2024, due to ARYA’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001140361-24-010146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.